Skip to main content

-

Technology Guidance - Drug

Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction Published on 2 May 2019


Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended listing sacubitril/valsartan on the Medication Assistance Fund (MAF) for treating chronic heart failure with reduced ejection fraction because of uncertain cost-effectiveness and budget impact at the price proposed by the manufacturer.



Get Acrobat Readeropens in a new window
Back to Top